Federated Hermes’s Damora Therapeutics DMRA Stock Holding History

Federated Hermes’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,000	Closed	-$252K	–	2139
2023 Q2	$252K	Hold	4,000	–	–	﹤0.01%	1517
2023 Q1	$199K	Hold	4,000	–	–	﹤0.01%	1584
2022 Q4	$115K	Buy	4,000 +1,600	+67%	+$66.4K	﹤0.01%	1621
2022 Q3	$113K	Buy	2,400 +800	+50%	+$40.6K	﹤0.01%	1601
2022 Q2	$69K	Buy	1,600 +560	+54%	+$25.7K	﹤0.01%	1646
2022 Q1	$57K	Hold	1,040	–	–	﹤0.01%	1719
2021 Q4	$79K	Buy	1,040 +240	+30%	+$18.8K	﹤0.01%	1739
2021 Q3	$72K	Buy	800 +320	+67%	+$34.2K	﹤0.01%	1814
2021 Q2	$61K	Sell	480 -320	-40%	-$43.6K	﹤0.01%	1847
2021 Q1	$122K	Hold	800	–	–	﹤0.01%	1764
2020 Q4	$250K	Buy	+800	New	+$298K	﹤0.01%	1659

Other funds holding DMRA

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes's DMRA Position: Q3 2023 in Review

Federated Hermes sold out of Damora Therapeutics (DMRA) in Q3 2023, closing a stake of 4,000 shares — an estimated $252K sold.

Federated Hermes first reported a position in DMRA in Q4 2020 and held it in 11 quarters. The position peaked at $252K in Q2 2023. 21 funds tracked by Wall St. Rank hold DMRA as of Q3 2023.

Federated Hermes reported no remaining Damora Therapeutics position as of Q3 2023 after selling out during the quarter.
Federated Hermes sold 4,000 Damora Therapeutics shares in Q3 2023, an estimated $252K.
Federated Hermes first reported a position in Damora Therapeutics in Q4 2020 and held it in 11 quarters.
Federated Hermes's Damora Therapeutics position peaked at $252K in Q2 2023.
21 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2023.

Based on Federated Hermes's 13F filing for Q3 2023, filed 13 Nov 2023.